Monopar Therapeutics Inc. (MNPR)

Market Cap	245.46M
Revenue (ttm)	n/a
Net Income (ttm)	-6.47M
Shares Out	6.10M
EPS (ttm)	-1.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,454
Open	40.36
Previous Close	40.97
Day's Range	38.98 - 44.16
52-Week Range	1.72 - 54.30
Beta	1.31
Analysts	Strong Buy
Price Target	43.00 (+6.83%)
Earnings Date	Mar 27, 2025

About MNPR

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNP...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 19, 2019
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: MNPR
• Website: https://www.monopartx.com

Analyst Forecast

According to 4 analysts, the average rating for MNPR stock is "Strong Buy." The 12-month stock price forecast is $43.0, which is an increase of 6.83% from the latest price.

Price Target

$43.0

(6.83% upside)

Analyst Consensus: Strong Buy